Zynex Inc (ZYXI) 0.2200 $ZYXI Zynex Announces June

New Post Public Reply Private Reply Replies (0) Message Board

Jul 27, 2016 at 12:06 AM

Zynex Inc (ZYXI) 0.2200 $ZYXI

Zynex Announces June Orders
PR Newswire - Fri Jul 22, 7:35AM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the amount of orders received in June for its electrotherapy product line.

Zynex Recognized in Top 100 Public Companies by ColoradoBiz
PR Newswire - Fri Jun 17, 7:55AM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today that ColoradoBiz Magazine has recognized Zynex in Top100 Public Companies in its May 2016 issue.

Zynex Hires Vice President of Operations
PR Newswire - Mon Jun 06, 7:20AM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the hire of David "Skip" Mogill as Vice President of Operations. Robert Cozart that had served in this position for over 9 years retired at the end of May this year.

Zynex Reports Electrotherapy Orders for May
PR Newswire - Thu Jun 02, 7:28AM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today May orders for the electrotherapy product line.

Zynex Hires Vice President of Finance
PR Newswire - Wed Jun 01, 7:00AM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the hire of Rick Luckenbill as Vice President of Finance. Paul Oberman, interim CFO consultant since October 2015 will still be available for the Company on an as-needed basis.

Zynex Announces First Quarter 2016 Results
PR Newswire - Wed May 25, 7:00AM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring, announced today its first quarter 2016 financial results.

Zynex Schedules 2016 First Quarter Earnings Release and Webcast
PR Newswire - Mon May 23, 5:58PM CDT
Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company's 2016 first quarter investor webcast on Wednesday, May 25, 2016 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time).

Zynex Reports Increase in Electrotherapy Orders for March
ACCESSWIRE - Fri Apr 08, 7:00AM CDT
LONE TREE, CO / ACCESSWIRE / April 8, 2016 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today March orders for the electrotherapy product line.

Zynex Announces 2015 Year End Results
ACCESSWIRE - Fri Apr 01, 7:00AM CDT
LONE TREE, CO / ACCESSWIRE / April 1, 2016 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today 2015 year-end financial results.

Zynex Schedules 2015 Year End Earnings Release and Webcast
ACCESSWIRE - Wed Mar 30, 5:41PM CDT
LONE TREE, CO / ACCESSWIRE / March 30, 2016 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company's 2015 year end investor webcast on Friday, April 1, 2016 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time.)

Zynex Provides Update on January Electrotherapy Orders
ACCESSWIRE - Tue Feb 02, 7:15AM CST
LONE TREE, CO / ACCESSWIRE / February 2, 2016 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announced today January orders for the electrotherapy product line.

Zynex Hires Chief Operating Officer for Growth Initiative
ACCESSWIRE - Wed Jan 27, 7:16AM CST
LONE TREE, CO / ACCESSWIRE / January 27, 2016 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announces today the hire of Michael Hartberger as Chief Operating Officer (COO).
PLT: 48.22 (+0.18)

Zynex Provides Update on Sales Growth
ACCESSWIRE - Tue Jan 05, 7:19AM CST
Electrotherapy Orders Increase by 150% in December

Zynex Appoints Distributor in Taiwan
ACCESSWIRE - Mon Dec 21, 7:30AM CST
LONE TREE, CO / ACCESSWIRE / December 21, 2015 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurodiagnostic equipment, cardiac and blood volume monitoring, announced today that it has appointed Deltason Medical as its distributor in Taiwan for its NeuroMove(TM) product line.

Zynex Provides Update on Electrotherapy Orders
ACCESSWIRE - Wed Dec 16, 7:30AM CST
December orders running ahead of forecast

Zynex Announces Third Quarter 2015 Results
ACCESSWIRE - Tue Nov 17, 7:31AM CST
LONE TREE, CO / ACCESSWIRE / November 17, 2015 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring and compound pharmacy, announced today its third quarter 2015 financial results.

Zynex Schedules Third Quarter 2015 Earnings Release and Webcast
ACCESSWIRE - Thu Nov 12, 7:30AM CST
LONE TREE, CO / ACCESSWIRE / November 12, 2015 / Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac and blood volume monitoring, and compound pharmacy, announced today that it will host the Company's third quarter investor webcast on Tuesday, November 17, 2015 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time).

Zynex files 510(k) application with US FDA for CM1500 for monitoring blood volume
M2 - Thu Sep 24, 5:50AM CDT
Medical technology company Zynex (Other OTC:ZYXI) said on Wednesday that it has filed an 510(k) application with the Food and Drug Administration pursuant to Section 510(k) of the Food, Drug and Cosmetic Act for clearance of its new CM1500 monitoring device.

Zynex, Inc. Announces FDA Filing for Blood Volume Monitor
ACCESSWIRE - Wed Sep 23, 1:56PM CDT
510(K) Application Filed For CM1500 with the Food and Drug Administration

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 298

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...